| Literature DB >> 32864919 |
Emin Can Ata1, Korhan Erkanli1, Mustafa Özer Ulukan1, Yahya Yıldız2, Halil Türkoglu1, Sedat Paslı1.
Abstract
OBJECTIVE: To compare peripheral and central cannulation techniques in cardiac reoperation.Entities:
Keywords: Aorta; Cardiopulmonary Bypass; Catheterization; Erythrocytes; Femoral Vein; Heart Atria; Heparin; Jugular Veins; Reoperation; Retrospective Studies; Sternotomy; Survival Rate
Mesh:
Year: 2020 PMID: 32864919 PMCID: PMC7454629 DOI: 10.21470/1678-9741-2019-0445
Source DB: PubMed Journal: Braz J Cardiovasc Surg ISSN: 0102-7638
Fig. 1Cannulation for peripheral cardiopulmonary bypass. A) Internal jugular vein cannulation; B) femoral artery and vein cannulation.
Fig. 2Decompression of huge right atrium with peripheral cardiopulmonary bypass. A) Preoperative chest X-ray; B) decompressed right atrium.
Preoperative clinical characteristics.
| CC (n=145) | PC (n=113) | ||
|---|---|---|---|
| Age (years) | 68.2±5.5 | 66.6±7.6 | 0.217 |
| Female | 65 (44.8%) | 42 (37.2%) | 0.216 |
| Diabetes mellitus | 24 (16.6%) | 17 (15.1%) | 0.743 |
| Hypertension | 25 (17.2%) | 22 (19.5%) | 0.646 |
| Peripheral vascular disease | 12 (8.3%) | 3 (2.7%) | 0.069 |
| Chronic obstructive pulmonary disease | 8 (5.5%) | 6 (5.3%) | 0.942 |
| Left ventricular ejection fraction (%) | 50.0±8.4 | 48.9±8.3 | 0.313 |
| EuroSCORE II | 7.19±2.94 | 7.35±3.13 | 0.242 |
| Similarity between the first and the reoperation types | |||
| Same | 82 (56.5%) | 49 (43.3%) | 0.036 |
| Different | 32 (22.1%) | 36 (31.9%) | 0.078 |
| Both | 31 (21.4%) | 28 (24.8%) | 0.519 |
CC=central cannulation; EuroSCORE=European System for Cardiac Operative Risk Evaluation; PC=peripheral cannulation
Distribution of reoperation types.
| CC | PC | Total | ||
|---|---|---|---|---|
| Isolated MVR | 50 (34.5) | 38 (33.6) | 88 (34.1) | 0.886 |
| Isolated CABG | 38 (26.2) | 17 (15.0) | 55 (21.3) | 0.032 |
| Isolated AVR | 26 (18.0) | 12 (10.6) | 38 (14.7) | 0.104 |
| Aortic procedures | 19 (13.1) | 23 (20.4) | 42 (16.3) | 0.120 |
| CABG+valvular | 7 (4.8) | 12 (10.6) | 19 (7.4) | 0.085 |
| Combined valvular | 5 (3.4) | 11 (9.7) | 16 (6.2) | 0.046 |
| Total | 145 (56.2) | 113 (43.8) | 258 (100) |
AVR=aortic valve replacement; CABG=coronary artery bypass grafting; CC=central cannulation; MVR=mitral valve replacement; PC=peripheral cannulation
Operative variables, blood transfusions, and major complications.
| CC (n=145) | PC (n=113) | ||
|---|---|---|---|
| Cardiopulmonary bypass time (min) | 120±26.7 | 125±31 | 0.008 |
| Aortic cross-clamp time (min) | 87.4±20.4 | 91.3±20.6 | 0.139 |
| Operation time (min) | 198±43 | 202±47 | 0.115 |
| Procedure-related injury | 12 (8.3%) | 2 (1.8%) | 0.038 |
| Right ventricle | 3 | 1 | |
| Right atrium | 2 | 1 | |
| Coronary vasculature | 3 | 0 | |
| Aorta | 1 | 0 | |
| Left innominate vein | 2 | 0 | |
| Inferior vena cava | 1 | 0 | |
| Postoperative bleeding (ml) | 744±315 | 720±296 | 0.204 |
| Red blood cell (pack) | 2.9±1.89 | 2.6±1.85 | 0.004 |
| Fresh frozen plasma (pack) | 0.94±1.44 | 0.96±1.35 | 0.723 |
| Cryoprecipitate (pack) | 0.44±1.42 | 0.41±1.32 | 0.672 |
| Platelet concentration (pack) | 0.45±1.35 | 0.46±1.38 | 0.973 |
| No blood transfusion patient | 21 (14.5%) | 12 (10.6%) | 0.358 |
| Reexploration | 11 (7.6%) | 3 (2.7%) | 0.097 |
| Renal failure | 7 (4.8%) | 6 (5.3%) | 0.860 |
| Pneumonia | 6 (4.1%) | 3 (2.7%) | 0.523 |
| Stroke | 7 (4.8%) | 4 (3.5%) | 0.613 |
| Cognitive disfunction | 11 (7.6%) | 5 (4.5%) | 0.302 |
| Wound complications | 6 (4.1%) | 5 (4.4%) | 0.909 |
| Sternal | 6 (4.1%) | 3 (2.7%) | |
| Femoral | 0 | 2 (1.8%) |
Odds ratio 5.01; 95% confidence interval 1.1-22.9
Defined as peak creatinine value ≥ 1.5 ´ preoperative value
CC=central cannulation; PC=peripheral cannulation
Postoperative follow-up and mortality.
| CC (n=145) | PC (n=113) | ||
|---|---|---|---|
| ICU stay (hours) | 33±12 | 29±15 | 0.160 |
| Prolonged ventilation (> 24 h) | 13 (9.0%) | 8 (7.1%) | 0.583 |
| IABP | 8 (5.5%) | 4 (3.5%) | 0.458 |
| Inotrope requirement (> 6 h) | 92 (63.0%) | 64 (56.6%) | 0.267 |
| Length of hospital stay (days) | 6.9±2.0 | 6.7±2.2 | 0.143 |
| Operative mortality | 4 (2.8%) | 0 | 0.186 |
| Hospital mortality (within first month) | 6 (4.3%) | 3 (2.7%) | 0.523 |
| One year survival (%) | 90.3 | 94.7 | 0.202 |
Includes operative mortality
CC=central cannulation; IABP=intra-aortic baloon pump; ICU=intensive care unit; PC=peripheral cannulation
Fig. 3Reoperation view with peripheral cardiopulmonary bypass. A) Mitral replacement for disfunctional mitral prosthesis; B) vein graft exposure for coronary artery bypass.
| Abbreviations, acronyms & symbols | |
|---|---|
| AVR | = Aortic valve replacement |
| CABG | = Coronary artery bypass grafting |
| CC | = Central cannulation |
| CPB | = Cardiopulmonary bypass |
| CT | = Computed tomography |
| EuroSCORE | = European System for Cardiac Operative Risk Evaluation |
| IABP | = Intra-aortic baloon pump |
| ICU | = Intensive care unit |
| IVC | = Inferior vena cava |
| MVR | = Mitral valve replacement |
| PC | = Peripheral cannulation |
| RBC | = Red blood cell |
| TEE | = Transesophageal echocardiography |
| Authors' roles & responsibilities | |
|---|---|
| ECA | Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; drafting the work or revising it critically for important intellectual content; final approval of the version to be published |
| KE | Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved; final approval of the version to be published |
| MOU | Drafting the work or revising it critically for important intellectual content; final approval of the version to be published |
| YY | Drafting the work or revising it critically for important intellectual content; final approval of the version to be published |
| HT | Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved; final approval of the version to be published |
| SP | Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; final approval of the version to be published |